Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression.
Journal Information
Full Title: Liver Cancer
Abbreviation: Liver Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology & Hepatology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Statement Naohiro Okano has received honoraria from Taiho Pharmaceutical, Eli Lilly Japan, Chugai Pharma, and Ono Pharmaceutical. Other authors declare no conflicts of interest associated with this manuscript."
"There were no funding sources for this manuscript."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025